FR2824567B1 - Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene - Google Patents

Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene

Info

Publication number
FR2824567B1
FR2824567B1 FR0106231A FR0106231A FR2824567B1 FR 2824567 B1 FR2824567 B1 FR 2824567B1 FR 0106231 A FR0106231 A FR 0106231A FR 0106231 A FR0106231 A FR 0106231A FR 2824567 B1 FR2824567 B1 FR 2824567B1
Authority
FR
France
Prior art keywords
regulators
obtaining
specific antigen
lymphocytes specific
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0106231A
Other languages
English (en)
French (fr)
Other versions
FR2824567A1 (fr
Inventor
Herve Groux
Francoise Cottrez
Abdelilah Wakkach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0106231A priority Critical patent/FR2824567B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to DE60218302T priority patent/DE60218302T2/de
Priority to AT02740789T priority patent/ATE354641T1/de
Priority to CA2446981A priority patent/CA2446981C/fr
Priority to ES02740789T priority patent/ES2282425T3/es
Priority to US10/477,671 priority patent/US8076133B2/en
Priority to EP02740789A priority patent/EP1390474B1/fr
Priority to PCT/FR2002/001586 priority patent/WO2002092793A1/fr
Priority to JP2002589661A priority patent/JP4185366B2/ja
Priority to DK02740789T priority patent/DK1390474T3/da
Publication of FR2824567A1 publication Critical patent/FR2824567A1/fr
Application granted granted Critical
Publication of FR2824567B1 publication Critical patent/FR2824567B1/fr
Priority to US11/928,189 priority patent/US20080233095A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/453—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR0106231A 2001-05-11 2001-05-11 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene Expired - Fee Related FR2824567B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0106231A FR2824567B1 (fr) 2001-05-11 2001-05-11 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
JP2002589661A JP4185366B2 (ja) 2001-05-11 2002-05-10 抗原−特異的Ｔｒ１リンパ球を得る方法
CA2446981A CA2446981C (fr) 2001-05-11 2002-05-10 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
ES02740789T ES2282425T3 (es) 2001-05-11 2002-05-10 Procedimiento de obtencion de linfocitos tr1 reguladores especificos de antigeno.
US10/477,671 US8076133B2 (en) 2001-05-11 2002-05-10 Method for obtaining antigen-specific Tr1 regulatory lymphocytes
EP02740789A EP1390474B1 (fr) 2001-05-11 2002-05-10 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
DE60218302T DE60218302T2 (de) 2001-05-11 2002-05-10 Verfahren zur gewinnung antigenspezifischer tr1-regualtorischer lymphozyten
AT02740789T ATE354641T1 (de) 2001-05-11 2002-05-10 Verfahren zur gewinnung antigenspezifischer tr1- regualtorischer lymphozyten
DK02740789T DK1390474T3 (da) 2001-05-11 2002-05-10 Fremgangsmåde til opnåelse af antigenspecifikke regulatoriske Tr-1-lymfocytter
PCT/FR2002/001586 WO2002092793A1 (fr) 2001-05-11 2002-05-10 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
US11/928,189 US20080233095A1 (en) 2001-05-11 2007-10-30 Method for obtaining antigen-specific tr1 regulatory lymphocytes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0106231A FR2824567B1 (fr) 2001-05-11 2001-05-11 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene

Publications (2)

Publication Number Publication Date
FR2824567A1 FR2824567A1 (fr) 2002-11-15
FR2824567B1 true FR2824567B1 (fr) 2003-08-08

Family

ID=8863160

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0106231A Expired - Fee Related FR2824567B1 (fr) 2001-05-11 2001-05-11 Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene

Country Status (10)

Country Link
US (2) US8076133B2 (cg-RX-API-DMAC7.html)
EP (1) EP1390474B1 (cg-RX-API-DMAC7.html)
JP (1) JP4185366B2 (cg-RX-API-DMAC7.html)
AT (1) ATE354641T1 (cg-RX-API-DMAC7.html)
CA (1) CA2446981C (cg-RX-API-DMAC7.html)
DE (1) DE60218302T2 (cg-RX-API-DMAC7.html)
DK (1) DK1390474T3 (cg-RX-API-DMAC7.html)
ES (1) ES2282425T3 (cg-RX-API-DMAC7.html)
FR (1) FR2824567B1 (cg-RX-API-DMAC7.html)
WO (1) WO2002092793A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
AU3066599A (en) 1998-03-03 1999-10-18 University Of Southern California Use of cytokines and mitogens to inhibit graft versus host disease
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
EP1463799A4 (en) * 2001-12-21 2006-01-18 Univ Southern California Methods for the induction of professional and cytokine-producing regulatory cells
US7670781B2 (en) 2002-01-03 2010-03-02 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal
US7638326B2 (en) * 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en) * 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
AU2003292137A1 (en) * 2002-11-29 2004-06-23 Maria Grazia Roncarolo Rapamycin and il-10 for the treatment of immune diseases
FR2852967B1 (fr) * 2003-03-26 2007-12-07 Txcell Procede d'obtention de cellules dendritiques et de cellules t
FR2856700B1 (fr) * 2003-06-24 2007-06-08 Txcell Procede d'identification de lymphocytes tr1 regulateurs par la presence et la surexpression de molecules specifiques et ses applications
AU2004288646A1 (en) * 2003-11-12 2005-05-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of lipopeptides for activating T lymphocytes through the skin
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CA2575689C (en) * 2004-08-11 2013-04-02 Txcell Tr1 cells for use in atherosclerosis
WO2006050138A2 (en) * 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
EP1712615A1 (en) * 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
NZ601439A (en) 2005-06-08 2012-11-30 Brigham & Womens Hospital Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
SI1739166T1 (sl) * 2005-07-01 2011-11-30 Txcell S A PRIDOBIVANJE CELIC Tr1 SPECIFIČNIH ZA ALIMENTARNI ANTIGEN ALI AVTOGEN IZ LEVKOCITNE ALI PBMC POPULACIJE
CA2619735C (en) * 2005-08-31 2014-05-27 Ith Immune Therapy Holdings Ab Treatment of inflammatory bowel disease
GB0603081D0 (en) * 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
US8124408B2 (en) * 2006-10-04 2012-02-28 Janssen Pharmaceutica N.V. Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
KR20100063052A (ko) * 2007-08-02 2010-06-10 아이에스에스 이뮨 시스템 스티뮬레이션 에이비 염증성 장 질환의 진단, 단계 구분 및 모니터링 방법
JP5539886B2 (ja) 2007-10-17 2014-07-02 ティクセル Ｔｒ１細胞、間葉系幹細胞およびその使用
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
EP2062970A1 (en) * 2007-11-26 2009-05-27 Txcell Compositions for treating an intestinal inflammatory condition
ES2393936T3 (es) 2008-04-28 2013-01-02 Txcell Composiciones para tratar una afección auto-inmune inflamatoria
EP2113560A1 (en) 2008-04-28 2009-11-04 TXCell Compositions for treating an arthritic condition
JP5520961B2 (ja) 2008-11-28 2014-06-11 エモリー ユニバーシティ 感染症および腫瘍を処置するための方法
TWI605828B (zh) 2008-12-09 2017-11-21 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
EP2221364A1 (en) * 2009-02-23 2010-08-25 TXCell Compositions for treating an allergic or asthmatic condition
EP2412802A1 (en) * 2010-07-29 2012-02-01 TXCell IL-13 producing TR1-like cells and use thereof
EP2439534A1 (en) * 2010-10-08 2012-04-11 TXCell Method for assessing the efficacy of a TR1 cell therapy in asubject
CA2831018A1 (en) 2011-03-25 2012-10-04 Txcell Method for using regulatory t cells in therapy
EP2982746A1 (en) 2014-08-07 2016-02-10 TXCell Regulatory T cells with therapeutic potential
US12343397B2 (en) 2018-05-17 2025-07-01 Regents Of The University Of Minnesota Drug-resistant immune cells and methods of use thereof
WO2019237378A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 一种将CD274基因定点整合至Jurkat细胞的方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277635B1 (en) * 1992-03-04 2001-08-21 Schering Corporation Use of interleukin-10 to produce a population of suppressor cells
CA2245170A1 (en) * 1996-02-08 1997-08-14 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating t cells
ATE347588T1 (de) * 1996-05-23 2006-12-15 Scripps Research Inst Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
US6746670B2 (en) * 2000-08-15 2004-06-08 Schering Corporation Regulatory T cells; methods
US6670146B2 (en) * 2000-10-04 2003-12-30 Schering Corporation Regulatory T cells; methods

Also Published As

Publication number Publication date
ATE354641T1 (de) 2007-03-15
DE60218302T2 (de) 2007-11-15
JP4185366B2 (ja) 2008-11-26
ES2282425T3 (es) 2007-10-16
CA2446981A1 (fr) 2003-11-21
JP2004526459A (ja) 2004-09-02
EP1390474A1 (fr) 2004-02-25
WO2002092793A1 (fr) 2002-11-21
US8076133B2 (en) 2011-12-13
CA2446981C (fr) 2012-03-20
FR2824567A1 (fr) 2002-11-15
US20080233095A1 (en) 2008-09-25
DE60218302D1 (de) 2007-04-05
DK1390474T3 (da) 2007-07-02
EP1390474B1 (fr) 2007-02-21
US20040191235A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
FR2824567B1 (fr) Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
JP2004526459A5 (cg-RX-API-DMAC7.html)
ES2182991T3 (es) Metodo para la preparar 3-haloalquil-1h-pirazoles.
AU3889399A (en) Vaccine delivery system
AU2999199A (en) Mesenchymal stem cells as immunosuppressants
AU3666800A (en) System and method for enhancing online support services using natural language interface for searching database
LU91367I2 (fr) Un vaccin à virus complet de l'influenza inactivéepréparé à partir d'une souche germe produite en u tlilisant la génétique inverse et facultativement comprenant un adjuvant
ATE270082T1 (de) Verfahren zur bereitung und transplantation von flachen implantaten und chirurgische geräte dafür
ATE221086T1 (de) Photovernetztes hyaluronsäuregel und verfahren zu dessen herstellung
GB2326321B (en) Method device, and article of manufacture for neural - network based generation of postlexical pronunciations from lexical pronunciations
DE59607005D1 (de) Steriles tropfbares ophthalmisches gelpräparat und verfahren zu dessen herstellung
WO2003038062A3 (en) Generation of use of tc1 and tc2 cells
ATE343175T1 (de) Dateitransfersystem, vorrichtung, verfahren und computerlesbares medium, das ein dateitransferprogramm speichert
ZA943782B (en) Immortalization of dendritic cells and generation of functional dendritic cell lines fully competent in antigen presentation and initiating primary T cell responses in vivo
GB9825096D0 (en) Cells,culture methods and their uses
DE69517191D1 (de) Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
AU5211200A (en) Method for diminishing specific immune reactions
WO1997011669A3 (en) MHC-class II restricted melanoma antigens and their use in therapeutic methods
DE59610629D1 (de) Immunogenes konstrukt, verfahren zu dessen herstellung und verwendung als vakzine
KR100391709B1 (en) Information interchange system for promoting community between family members
Huang et al. Location–Positioning Tregs to the right place at the right time
Lafferty By his own device.
WANG et al. Expression of costimulatory molecules on peripheral blood lymphocytes in patients with Beh et's disease
Tosi et al. Regulation of MHC class I and class II and of CD4 expression by HIV-TAT
EP0765935A3 (en) Growth environment assembly and method of use thereof

Legal Events

Date Code Title Description
CL Concession to grant licences
ST Notification of lapse

Effective date: 20110131